RE: Update22 Dec 2015 11:46
The impact of impairment would be less than £2m. Total investment £2.5m, less proceeds from sale USD 700k, and ACE also get access to Ziolar's intellectual property for a period of 2 years.
Let's assume worst scenario ie impairment of £2m.
Last year profits were £4.8m, assuming 10% decline lets say trading profit this year would be £4.3m.
Still we are looking at the year-end final profitability figure of £2.3m which is above the current M.Cap.
Seriously buying at this price is nothing but a steal. But not sure why the market and big investors are still ignoring this Co. and no broker recommendations for last 2 months.
We understand why this stock went so low, because of a couple of negative RNSs combined with negative perception about the Chinese stocks. But this panic in the market should be over by now. The Co. is very much in front of us here, making profits, majority shares are with the management, where is the justification for this market cap. And on working capital, I am sure the problem is over now after that injection of £1.7m in June.
All I can say is discipline is the key, we may need to wait for a bit longer for the right price.